AP783A - Composition of L-oddC Compound derivatives and methods of use as antineoplastic agents. - Google Patents

Composition of L-oddC Compound derivatives and methods of use as antineoplastic agents. Download PDF

Info

Publication number
AP783A
AP783A APAP/P/1997/000939A AP9700939A AP783A AP 783 A AP783 A AP 783A AP 9700939 A AP9700939 A AP 9700939A AP 783 A AP783 A AP 783A
Authority
AP
ARIPO
Prior art keywords
composition
tumor
cancer
pharmaceutically acceptable
compound
Prior art date
Application number
APAP/P/1997/000939A
Other languages
English (en)
Other versions
AP9700939A0 (en
Inventor
Chung K Chu
Young-Chi Cheng
Original Assignee
Univ Georgia
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/301,298 external-priority patent/US5817667A/en
Application filed by Univ Georgia, Univ Yale filed Critical Univ Georgia
Publication of AP9700939A0 publication Critical patent/AP9700939A0/xx
Application granted granted Critical
Publication of AP783A publication Critical patent/AP783A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
APAP/P/1997/000939A 1994-09-06 1995-09-05 Composition of L-oddC Compound derivatives and methods of use as antineoplastic agents. AP783A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/301,298 US5817667A (en) 1991-04-17 1994-09-06 Compounds and methods for the treatment of cancer
US39063395A 1995-02-17 1995-02-17
PCT/US1995/011464 WO1996007413A1 (en) 1994-09-06 1995-09-05 Compounds and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
AP9700939A0 AP9700939A0 (en) 1997-04-30
AP783A true AP783A (en) 1999-11-17

Family

ID=26972285

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/000939A AP783A (en) 1994-09-06 1995-09-05 Composition of L-oddC Compound derivatives and methods of use as antineoplastic agents.

Country Status (31)

Country Link
US (3) US6063787A (is)
EP (2) EP0781136B1 (is)
JP (1) JP3979662B2 (is)
KR (1) KR100374477B1 (is)
CN (3) CN1111409C (is)
AP (1) AP783A (is)
AT (1) ATE267015T1 (is)
AU (1) AU704977B2 (is)
BG (1) BG63122B1 (is)
BR (1) BR9508886A (is)
CA (1) CA2199117C (is)
CZ (1) CZ297873B6 (is)
DE (1) DE69533066T2 (is)
DK (1) DK0781136T3 (is)
ES (1) ES2219666T3 (is)
FI (1) FI970918A7 (is)
HU (1) HUT77172A (is)
IL (1) IL115156A (is)
IS (1) IS2011B (is)
MY (1) MY121548A (is)
NO (1) NO313268B1 (is)
NZ (1) NZ335013A (is)
OA (1) OA10473A (is)
PL (2) PL188359B1 (is)
PT (1) PT781136E (is)
RO (1) RO118748B1 (is)
RU (1) RU2168995C2 (is)
SI (1) SI0781136T1 (is)
SK (1) SK284564B6 (is)
WO (1) WO1996007413A1 (is)
ZA (1) ZA957483B (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
DE69840216D1 (de) 1997-08-08 2008-12-24 Celmed Oncology Usa Inc Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
ES2172303T3 (es) 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
EA200700564A1 (ru) 1998-02-25 2007-08-31 Эмори Юниверсити 2`-фторнуклеозиды
AU2004201676B2 (en) * 1999-03-29 2006-03-09 University Of Georgia Research Foundation, Inc. Methods of treating leukemia
CZ20013483A3 (cs) * 1999-03-29 2002-04-17 Shire Biochem Inc. Pouľití sloučenin podle vynálezu pro přípravu farmaceutických přípravků k léčení leukémie
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
ATE269081T1 (de) 1999-09-24 2004-07-15 Shire Biochem Inc Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1634888A3 (en) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
AU1201502A (en) * 2000-10-13 2002-04-22 Shire Biochem Inc Dioxolane analogs for improved inter-cellular delivery
EP1359921A4 (en) 2001-01-19 2006-09-06 Newbiotics Inc METHODS RELATING TO THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
CN1744902B (zh) * 2001-03-23 2010-05-26 希拉加拿大股份有限公司 治疗癌症的药物组合
DE60234577D1 (de) * 2001-03-23 2010-01-14 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
US20030027799A1 (en) * 2001-03-30 2003-02-06 Shire Biochem Inc. Methods of treating cancer using a combination of drugs
US6645972B2 (en) 2001-11-02 2003-11-11 Shire Biochem Inc. Methods of treating leukemia
US7858662B2 (en) * 2001-11-19 2010-12-28 Medigene Ag Medicament for the treatment of viral skin and tumour diseases
CN1556988B (zh) 2002-06-21 2011-09-14 Lg电子株式会社 具有用于管理记录在其上面的视频数据的再现的数据结构的记录介质
EP1516329A4 (en) 2002-06-21 2009-07-15 Lg Electronics Inc RECORDING MEDIUM WITH A DATA STRUCTURE FOR MANAGING THE REPRODUCTION OF RECORDED VIDEO DATA
WO2004001752A1 (en) 2002-06-24 2003-12-31 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple title video data recorded thereon and recording and reproducing methods and apparatuses
KR20040000290A (ko) 2002-06-24 2004-01-03 엘지전자 주식회사 고밀도 광디스크의 멀티 경로 데이터 스트림 관리방법
CN1565031B (zh) 2002-06-28 2010-09-29 Lg电子株式会社 一种用于管理多个路径数据的记录和再现的方法及装置
CA2499738A1 (en) * 2002-09-24 2004-04-08 Novartis Ag Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
JP4431043B2 (ja) 2002-10-14 2010-03-10 エルジー エレクトロニクス インコーポレイティド 記録された複数のオーディオストリームの再生を管理するためのデータ構造を有する光ディスク、それによる記録及び再生方法及び装置
CA2469178C (en) 2002-10-15 2009-09-01 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple graphics streams recorded thereon and recording and reproducing methods and apparatuses
CA2473309C (en) 2002-11-12 2009-09-08 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
US7606463B2 (en) 2003-02-24 2009-10-20 Lg Electronics, Inc. Recording medium having data structure for managing playback control and recording and reproducing methods and apparatuses
US7693394B2 (en) 2003-02-26 2010-04-06 Lg Electronics Inc. Recording medium having data structure for managing reproduction of data streams recorded thereon and recording and reproducing methods and apparatuses
US7809775B2 (en) 2003-02-27 2010-10-05 Lg Electronics, Inc. Recording medium having data structure for managing playback control recorded thereon and recording and reproducing methods and apparatuses
CN100397882C (zh) 2003-02-28 2008-06-25 Lg电子株式会社 具有用于管理记录其上的视频数据的随机/洗牌重现的数据结构的记录媒体以及记录和重现的方法和装置
US7620301B2 (en) 2003-04-04 2009-11-17 Lg Electronics Inc. System and method for resuming playback
BRPI0415215B8 (pt) 2003-10-09 2021-05-25 Medigene Ag uso de polifenol na preparação de medicamento
EA016838B1 (ru) * 2005-06-07 2012-07-30 Йельский Университет Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt)
US7951788B2 (en) * 2005-12-02 2011-05-31 Yale University Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs
NO324263B1 (no) * 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
WO2008030373A2 (en) * 2006-09-01 2008-03-13 University Of Georgia Research Foundation, Inc. L- oddc prodrugs for cancer
RU2322243C1 (ru) * 2006-10-20 2008-04-20 Наталья Юрьевна Костюкова Фармацевтическая композиция для лечения поражений роговицы
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
DK3562946T3 (da) * 2016-12-28 2022-01-31 Transgene Sa Oncolytiske virusser og terapeutiske molekyler
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
EP0337713A2 (en) * 1988-04-11 1989-10-18 Biochem Pharma Inc 2-Substituted-4-Substituted-1,3-Dioxolanes, Synthesis and use thereof
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
DK224286A (da) * 1985-05-15 1986-11-16 Wellcome Found 2',3'-dideoxy-nucleosider
JPS62501712A (ja) * 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
EP0217580A3 (en) * 1985-09-17 1990-11-07 The Wellcome Foundation Limited Therapeutic nucleosides
IN164556B (is) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
FR2601385B1 (fr) * 1986-07-09 1989-09-29 Sucre Rech & Dev Procede de preparation a partir de saccharose d'un melange de sucres a haute teneur en isomaltose par voie enzymatique et produits obtenus
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
EP0342203B1 (en) * 1987-03-24 1994-07-06 Nycomed Imaging As 2',3' dideoxyribofuranoxide derivatives
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
CA2005815C (en) * 1988-12-19 1999-08-03 Wellcome Foundation Limited (The) Antiviral acyclic nucleoside derivatives
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
WO1995018137A1 (en) * 1993-12-30 1995-07-06 Genta Incorporated Improved process for the purification of oligomers
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5971983A (en) * 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
EP0337713A2 (en) * 1988-04-11 1989-10-18 Biochem Pharma Inc 2-Substituted-4-Substituted-1,3-Dioxolanes, Synthesis and use thereof
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections

Also Published As

Publication number Publication date
CA2199117A1 (en) 1996-03-14
EP0781136A1 (en) 1997-07-02
US6063787A (en) 2000-05-16
CA2199117C (en) 2006-04-11
ZA957483B (en) 1997-06-06
SK284564B6 (sk) 2005-06-02
IS4434A (is) 1997-03-04
SK28197A3 (en) 1997-09-10
DK0781136T3 (da) 2004-08-02
DE69533066T2 (de) 2005-06-02
CN1251680C (zh) 2006-04-19
KR970705393A (ko) 1997-10-09
US8076347B2 (en) 2011-12-13
CN1827108A (zh) 2006-09-06
RO118748B1 (ro) 2003-10-30
ATE267015T1 (de) 2004-06-15
PL318971A1 (en) 1997-07-21
IL115156A (en) 2000-07-16
MY121548A (en) 2006-02-28
KR100374477B1 (ko) 2003-06-19
NO971015D0 (no) 1997-03-05
CZ63397A3 (en) 1997-07-16
EP1468687A1 (en) 2004-10-20
OA10473A (en) 2002-04-08
PT781136E (pt) 2004-09-30
SI0781136T1 (en) 2004-08-31
EP0781136A4 (en) 1999-06-23
FI970918L (fi) 1997-05-02
US7262213B2 (en) 2007-08-28
US20050261320A1 (en) 2005-11-24
AU704977B2 (en) 1999-05-13
DE69533066D1 (de) 2004-06-24
PL188359B1 (pl) 2005-01-31
AU3586295A (en) 1996-03-27
WO1996007413A1 (en) 1996-03-14
CN1111409C (zh) 2003-06-18
EP0781136B1 (en) 2004-05-19
HUT77172A (hu) 1998-03-02
ES2219666T3 (es) 2004-12-01
JPH10506385A (ja) 1998-06-23
RU2168995C2 (ru) 2001-06-20
PL189288B1 (pl) 2005-07-29
FI970918A7 (fi) 1997-05-02
NZ335013A (en) 2000-07-28
US20080171758A1 (en) 2008-07-17
CN1160351A (zh) 1997-09-24
NO971015L (no) 1997-03-05
CN1448142A (zh) 2003-10-15
AP9700939A0 (en) 1997-04-30
CZ297873B6 (cs) 2007-04-18
IL115156A0 (en) 1995-12-31
BG101284A (bg) 1998-03-31
BR9508886A (pt) 1997-12-30
JP3979662B2 (ja) 2007-09-19
FI970918A0 (fi) 1997-03-04
NO313268B1 (no) 2002-09-09
BG63122B1 (bg) 2001-04-30
IS2011B (is) 2005-05-13

Similar Documents

Publication Publication Date Title
AP783A (en) Composition of L-oddC Compound derivatives and methods of use as antineoplastic agents.
US5817667A (en) Compounds and methods for the treatment of cancer
BG63121B1 (bg) Таксоиди, тяхното получаване и фармацевтични състави, които ги съдържат
US8399420B2 (en) Azacytidine analogues and uses thereof
HU203363B (en) Process for producing 2',3'-dideoxy-2',2'-difluoronucleosides and pharmaceutical compositions comprising same as active ingredient
US6436948B1 (en) Method for the treatment of psoriasis and genital warts
EP0180897B1 (en) 5-fluorouracil derivatives
RU2347786C2 (ru) Производные сложноэфирных липидов нуклеотидов
JP5185823B2 (ja) がん治療用ジオキソラン誘導体
HK1095084A (en) The use of cytosine derivatives for the manufacture of a medicament for the treatment of tumors
NO854692L (no) Fremgangsmaate ved fremstilling av imidazopyridazinderivater.